Scope Fluidics

Molecular diagnostics · Rapid pathogen ID & AST

Overview

Diagnostics developer behind a landmark Polish biotech exit — sold its PCR|ONE rapid-PCR system to bioMérieux; BacterOMIC antibiotic-susceptibility system advancing.

What they do

Scope Fluidics is a Warsaw Stock Exchange-listed medical diagnostics developer that builds rapid molecular and microbiology systems through dedicated project companies. Its model is to incubate breakthrough diagnostic platforms to a high-value stage and then monetize them via strategic sales to global diagnostics players.

Lead program & status

Its flagship platform was PCR|ONE, a rapid-PCR system for fast pathogen identification, developed under the Curiosity Diagnostics subsidiary. In a landmark Polish life-sciences transaction, Scope Fluidics agreed to sell the project to Bio-Rad Laboratories: an upfront payment of roughly USD 100 million plus milestones, with a 2024 settlement bringing the total to about USD 130 million, frequently cited as the largest deal in the history of Poland's life-sciences sector. (Note: some sources reference different acquirers in coverage of the rapid-diagnostics space, but the PCR|ONE asset was sold to Bio-Rad.) Its second platform, BacterOMIC, is an advanced antibiotic-susceptibility testing (AST) system that quantifies clinically relevant antibiotics and identifies synergistic pairs; an Early Access Program launched in late 2023, and the company has signaled a potential strategic deal as the priority for BacterOMIC.

Why it matters

Scope Fluidics is a proof point that Polish deep-tech diagnostics can reach a major international exit, and BacterOMIC addresses the urgent global challenge of antimicrobial resistance.

FAQ

What did Scope Fluidics sell to Bio-Rad?

It sold its PCR|ONE rapid-PCR pathogen-identification system (via the Curiosity Diagnostics subsidiary) to Bio-Rad Laboratories, with a total transaction value reaching about USD 130 million after a 2024 settlement.

What is BacterOMIC?

BacterOMIC is Scope Fluidics' antibiotic-susceptibility testing system that quantifies clinically relevant antibiotics and identifies synergistic antibiotic pairs; it entered an Early Access Program in late 2023.

Why is Scope Fluidics significant for Polish biotech?

The PCR|ONE sale is frequently described as the largest deal in the history of Poland's life-sciences sector, demonstrating that Polish diagnostics can achieve major international exits.

Company website / source ↗ Open the interactive map →